Literature DB >> 23999429

Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses.

Natalie J Thornburg, David P Nannemann, David L Blum, Jessica A Belser, Terrence M Tumpey, Shyam Deshpande, Gloria A Fritz, Gopal Sapparapu, Jens C Krause, Jeong Hyun Lee, Andrew B Ward, David E Lee, Sheng Li, Katie L Winarski, Benjamin W Spiller, Jens Meiler, James E Crowe.   

Abstract

Recent studies described the experimental adaptation of influenza H5 HAs that confers respiratory droplet transmission (rdt) to influenza virus in ferrets. Acquisition of the ability to transmit via aerosol may lead to the development of a highly pathogenic pandemic H5 virus. Vaccines are predicted to play an important role in H5N1 control should the virus become readily transmissible between humans. We obtained PBMCs from patients who received an A/Vietnam/1203/2004 H5N1 subunit vaccine. Human hybridomas were then generated and characterized. We identified antibodies that bound the HA head domain and recognized both WT and rdt H5 HAs. We used a combination of structural techniques to define a mechanism of antibody recognition of an H5 HA receptor-binding site that neutralized H5N1 influenza viruses and pseudoviruses carrying the HA rdt variants that have mutations near the receptor-binding site. Incorporation or retention of this critical antigenic site should be considered in the design of novel H5 HA immunogens to protect against mammalian-adapted H5N1 mutants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999429      PMCID: PMC3784541          DOI: 10.1172/JCI69377

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  13 in total

1.  An antibody that prevents the hemagglutinin low pH fusogenic transition.

Authors:  C Barbey-Martin; B Gigant; T Bizebard; L J Calder; S A Wharton; J J Skehel; M Knossow
Journal:  Virology       Date:  2002-03-01       Impact factor: 3.616

2.  Airborne transmission of influenza A/H5N1 virus between ferrets.

Authors:  Sander Herfst; Eefje J A Schrauwen; Martin Linster; Salin Chutinimitkul; Emmie de Wit; Vincent J Munster; Erin M Sorrell; Theo M Bestebroer; David F Burke; Derek J Smith; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

3.  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

Authors:  David I Bernstein; Kathryn M Edwards; Cornelia L Dekker; Robert Belshe; Helen K B Talbot; Irene L Graham; Diana L Noah; Fenhua He; Heather Hill
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

4.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Authors:  James R R Whittle; Ruijun Zhang; Surender Khurana; Lisa R King; Jody Manischewitz; Hana Golding; Philip R Dormitzer; Barton F Haynes; Emmanuel B Walter; M Anthony Moody; Thomas B Kepler; Hua-Xin Liao; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

5.  Refinement of protein structures into low-resolution density maps using rosetta.

Authors:  Frank DiMaio; Michael D Tyka; Matthew L Baker; Wah Chiu; David Baker
Journal:  J Mol Biol       Date:  2009-07-08       Impact factor: 5.469

6.  Structure of influenza virus haemagglutinin complexed with a neutralizing antibody.

Authors:  T Bizebard; B Gigant; P Rigolet; B Rasmussen; O Diat; P Bösecke; S A Wharton; J J Skehel; M Knossow
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

7.  Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

Authors:  Xiaocong Yu; Tshidi Tsibane; Patricia A McGraw; Frances S House; Christopher J Keefer; Mark D Hicar; Terrence M Tumpey; Claudia Pappas; Lucy A Perrone; Osvaldo Martinez; James Stevens; Ian A Wilson; Patricia V Aguilar; Eric L Altschuler; Christopher F Basler; James E Crowe
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

8.  Benchmarking and analysis of protein docking performance in Rosetta v3.2.

Authors:  Sidhartha Chaudhury; Monica Berrondo; Brian D Weitzner; Pravin Muthu; Hannah Bergman; Jeffrey J Gray
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

9.  Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets.

Authors:  Masaki Imai; Tokiko Watanabe; Masato Hatta; Subash C Das; Makoto Ozawa; Kyoko Shinya; Gongxun Zhong; Anthony Hanson; Hiroaki Katsura; Shinji Watanabe; Chengjun Li; Eiryo Kawakami; Shinya Yamada; Maki Kiso; Yasuo Suzuki; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Nature       Date:  2012-05-02       Impact factor: 49.962

10.  A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin.

Authors:  Rui Xu; Jens C Krause; Ryan McBride; James C Paulson; James E Crowe; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2013-02-10       Impact factor: 15.369

View more
  20 in total

Review 1.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

2.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

3.  Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites.

Authors:  Katie L Winarski; Natalie J Thornburg; Yingchun Yu; Gopal Sapparapu; James E Crowe; Benjamin W Spiller
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 4.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

5.  Antibody Determinants of Influenza Immunity.

Authors:  James E Crowe
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

6.  Recognition of influenza H3N2 variant virus by human neutralizing antibodies.

Authors:  Sandhya Bangaru; Travis Nieusma; Nurgun Kose; Natalie J Thornburg; Jessica A Finn; Bryan S Kaplan; Hannah G King; Vidisha Singh; Rebecca M Lampley; Gopal Sapparapu; Alberto Cisneros; Kathryn M Edwards; James C Slaughter; Srilatha Edupuganti; Lilin Lai; Juergen A Richt; Richard J Webby; Andrew B Ward; James E Crowe
Journal:  JCI Insight       Date:  2016-07-07

7.  Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.

Authors:  Gopal Sapparapu; Estefania Fernandez; Nurgun Kose; Julie M Fox; Robin G Bombardi; Haiyan Zhao; Christopher A Nelson; Aubrey L Bryan; Trevor Barnes; Edgar Davidson; Indira U Mysorekar; Daved H Fremont; Benjamin J Doranz; Michael S Diamond; James E Crowe
Journal:  Nature       Date:  2016-11-07       Impact factor: 49.962

Review 8.  Influenza Virus-Specific Human Antibody Repertoire Studies.

Authors:  James E Crowe
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

9.  H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.

Authors:  Natalie J Thornburg; Heng Zhang; Sandhya Bangaru; Gopal Sapparapu; Nurgun Kose; Rebecca M Lampley; Robin G Bombardi; Yingchun Yu; Stephen Graham; Andre Branchizio; Sandra M Yoder; Michael T Rock; C Buddy Creech; Kathryn M Edwards; David Lee; Sheng Li; Ian A Wilson; Adolfo García-Sastre; Randy A Albrecht; James E Crowe
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

10.  Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.

Authors:  Seth J Zost; Jinhui Dong; Iuliia M Gilchuk; Pavlo Gilchuk; Natalie J Thornburg; Sandhya Bangaru; Nurgun Kose; Jessica A Finn; Robin Bombardi; Cinque Soto; Elaine C Chen; Rachel S Nargi; Rachel E Sutton; Ryan P Irving; Naveenchandra Suryadevara; Jonna B Westover; Robert H Carnahan; Hannah L Turner; Sheng Li; Andrew B Ward; James E Crowe
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.